Clinical Trial News and Research

RSS

CEL-SCI's Multikine cancer drug receives key Japanese patent

CEL-SCI Corporation today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection).

29 Nov 2012

FDA approves Velomedix’s IDE to expand design of VELOCITY trial for heart attack

Velomedix, Inc., a venture-backed medical device company advancing the field of therapeutic hypothermia, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to expand the design of its VELOCITY pilot clinical trial.

29 Nov 2012

NovImmune commences NI-0101 Phase I clinical trial in arthritis

NovImmune SA initiated dosing in a Phase I clinical trial of NI-0101, a monoclonal antibody drug candidate targeting toll-like receptor-4 (TLR4).

29 Nov 2012

Two-route drug combination best for horse joint pain

A combination of systemic nonsteroidal anti-inflammatory drugs plus intrasynovial glucocorticosteroids is superior to either medication alone in improving outcomes for lame horses with perisynovial pain of the metacarpophalangeal joint, report Dutch researchers.

28 Nov 2012

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Medication development efforts for cocaine dependence have yet to result in an FDA approved treatment. The powerful rewarding effects of cocaine, the profound disruptive impact of cocaine dependence on one's lifestyle, and the tendency of cocaine to attract people who make poor life choices and then exacerbate impulsive behavior all make cocaine a vexing clinical condition.

28 Nov 2012

Vitamin D may help prevent dental caries

A new review of existing studies points toward a potential role for vitamin D in helping to prevent dental caries, or tooth decay.

28 Nov 2012

Enrollment begins in Elan’s ELND005 Phase 2 trial for agitation/aggression associated with AD

Elan Corporation, plc today announced that it has enrolled the first patient in a Phase 2 clinical trial of ELND005 (Study AG201) for the treatment of agitation/aggression in patients with moderate to severe Alzheimer's disease (AD).

28 Nov 2012

Amarantus demonstrates excellent diffusion profile of MANF in the striatum of rat brains

Amarantus BioSciences, Inc., a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

27 Nov 2012

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis.

27 Nov 2012

Rhythm raises additional $8 million to complete Series B financing

Rhythm announced today that the company has raised an additional $8 million to complete a $33 million Series B financing.

27 Nov 2012

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease is a very broad family of diseases. There are two main categories of liver disease:

27 Nov 2012

Researchers discover LSD-1 enzyme as important target for treatment of Ewing sarcoma

Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults, and the previously unknown mechanism behind it, come hand-in-hand in a new study by researchers from Huntsman Cancer Institute (HCI) at the University of Utah. The report appears in today's online issue of the journal Oncogene.

26 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Enrollment complete in Tryton's Pivotal IDE Side Branch Stent trial to treat bifurcation lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the completion of enrollment in the TRYTON Pivotal IDE trial evaluating the Tryton Side Branch Stent.

26 Nov 2012

Apitope announces completion of recruitment in ATX-MS-1467 Phase I trial for MS

Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS).

26 Nov 2012

Allon Files Preliminary Shelf Prospectus

Allon Therapeutics Inc. has filed a preliminary short form base shelf prospectus with the securities commissions in each province and territory of Canada (other than Quebec).

23 Nov 2012

Tumour burden predicts prognosis in mRCC

Tumor burden plays an independent prognostic and predictive role in metastatic renal cell carcinoma, a clinical trial shows.

22 Nov 2012

Citicoline not superior to placebo in treating traumatic brain injury

Although approved for use for treating traumatic brain injury (TBI) in nearly 60 countries, use of citicoline in a randomized trial that included more than 1,200 participants with TBI did not result in improvement in functional and cognitive status, according to a study appearing in the November 21 issue of JAMA.

22 Nov 2012

Regorafenib able to control resistant gastrointestinal stromal tumor

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

21 Nov 2012

Musical tones can reset the brain and effectively reduce insomnia

If you are among the 50 percent of Americans who suffer from insomnia, then you have probably tried everything – from warm milk to melatonin pills or prescription medications to induce sleep – with varying degrees of success and side effects. But what if sleep could be achieved not by a substance, but through 'balancing' brain activity?

21 Nov 2012

Clinical Trial News and Research

CEL-SCI's Multikine cancer drug receives key Japanese patent

FDA approves Velomedix’s IDE to expand design of VELOCITY trial for heart attack

NovImmune commences NI-0101 Phase I clinical trial in arthritis

Two-route drug combination best for horse joint pain

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Vitamin D may help prevent dental caries

Enrollment begins in Elan’s ELND005 Phase 2 trial for agitation/aggression associated with AD

Amarantus demonstrates excellent diffusion profile of MANF in the striatum of rat brains

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Rhythm raises additional $8 million to complete Series B financing

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Researchers discover LSD-1 enzyme as important target for treatment of Ewing sarcoma

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Enrollment complete in Tryton's Pivotal IDE Side Branch Stent trial to treat bifurcation lesions

Apitope announces completion of recruitment in ATX-MS-1467 Phase I trial for MS

Allon Files Preliminary Shelf Prospectus

Tumour burden predicts prognosis in mRCC

Citicoline not superior to placebo in treating traumatic brain injury

Regorafenib able to control resistant gastrointestinal stromal tumor

Musical tones can reset the brain and effectively reduce insomnia

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer